MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15135121

Медицинская библиотека · Journal of clinical medicine · 2026

From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis.

Yaşargün Duygu Özkan, Türkoğlu Recai

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

Cladribine is a high-efficacy immune reconstitution therapy for relapsing multiple sclerosis, but additional real-world data remain valuable, particularly from single-center cohorts with combined clinical, radiological, and laboratory follow-up. This study aimed to evaluate the 24-month effectiveness and safety of cladribine in patients with relapsing-remitting multiple sclerosis (RRMS), with a particular focus on no evidence of disease activity (NEDA-3) and lymphopenia.

Methods

This retrospective single-center observational cohort study included adults with RRMS treated with cladribine who had at least 24 months of clinical and MRI follow-up. NEDA-3 was defined as the absence of clinical relapses, disability progression, and MRI activity. Brain MRI was performed at 6, 12, and 24 months. Absolute lymphocyte counts were monitored longitudinally, and lymphopenia was graded according to standard criteria.

Results

A total of 71 patients were included. NEDA-3 was achieved in 61 patients (85.9%) at 12 months and 50 patients (70.4%) at 24 months. No demographic or baseline clinical variable was independently associated with NEDA-3 at either time point. Lymphopenia occurred in 53 patients (74.6%), including grade 1 in 14 (19.7%), grade 2 in 23 (32.4%), grade 3 in 14 (19.7%), and grade 4 in 2 (2.8%). One patient developed herpes zoster infection during follow-up.

Conclusions

Cladribine demonstrated durable effectiveness and a manageable safety profile over 24 months in a real-world RRMS population. The close alignment between our findings and those reported in pivotal clinical trials underscores the external validity of cladribine efficacy beyond controlled study environments. These data provide valuable real-world evidence bridging the gap between controlled research settings and everyday patient care, thereby strengthening the evidence base for cladribine in contemporary MS management.

Для цитирования: Yaşargün Duygu Özkan, Türkoğlu Recai. From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15135121.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.